Novartis AG $NVS Shares Acquired by Henshaw Capital LLC

Henshaw Capital LLC boosted its holdings in Novartis AG (NYSE:NVS) by 152.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,295 shares of the company’s stock after purchasing an additional 7,430 shares during the quarter. Henshaw Capital LLC’s holdings in Novartis were worth $1,878,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of NVS. Archer Investment Corp raised its holdings in shares of Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after buying an additional 80 shares during the last quarter. Arlington Trust Co LLC acquired a new position in Novartis in the 4th quarter valued at about $25,000. CrossGen Wealth LLC acquired a new position in Novartis in the 4th quarter valued at about $28,000. Bank of Jackson Hole Trust grew its stake in shares of Novartis by 425.0% in the 4th quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 187 shares during the last quarter. Finally, Nalls Sherbakoff Group LLC purchased a new stake in shares of Novartis during the fourth quarter worth approximately $34,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVS has been the topic of a number of recent analyst reports. Citigroup reaffirmed a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Trading Down 1.4%

Shares of NVS stock opened at $156.18 on Friday. The company has a market capitalization of $298.01 billion, a price-to-earnings ratio of 23.56, a PEG ratio of 2.67 and a beta of 0.45. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The firm has a 50-day moving average price of $152.66 and a 200 day moving average price of $152.72. Novartis AG has a twelve month low of $112.34 and a twelve month high of $170.46.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The business had revenue of $14.95 billion during the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. Research analysts forecast that Novartis AG will post 8.85 earnings per share for the current fiscal year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.